Equities researchers at UBS Group assumed coverage on shares of Akoya Biosciences (NASDAQ:AKYA – Get Rating) in a research note issued on Thursday, The Fly reports. The brokerage set a "buy" rating and a $14.00 price target on the stock. UBS Group's target price would indicate a potential upside of 16.76% from the stock's current price.

Several other equities analysts have also issued reports on the stock. Stephens started coverage on shares of Akoya Biosciences in a report on Wednesday, October 5th. They set an "overweight" rating and a $16.00 price objective on the stock. Capital One Financial assumed coverage on shares of Akoya Biosciences in a report on Thursday, November 3rd. They issued an "overweight" rating and a $19.00 price target on the stock. Finally, BTIG Research cut their price target on shares of Akoya Biosciences to $18.00 in a report on Tuesday, November 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akoya Biosciences currently has a consensus rating of "Buy" and a consensus target price of $17.17.

Akoya Biosciences Stock Down 4.2 %

AKYA opened at $11.99 on Thursday. The firm has a 50-day simple moving average of $11.07 and a two-hundred day simple moving average of $12.28. Akoya Biosciences has a 52 week low of $8.02 and a 52 week high of $16.57. The company has a market capitalization of $455.14 million, a PE ratio of -6.48 and a beta of 1.10. The company has a quick ratio of 3.11, a current ratio of 3.53 and a debt-to-equity ratio of 0.71.

Insider Transactions at Akoya Biosciences

In other news, CFO Joseph Driscoll sold 24,613 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $12.54, for a total transaction of $308,647.02. Following the completion of the sale, the chief financial officer now owns 12,500 shares of the company's stock, valued at $156,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Joseph Driscoll sold 24,613 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $12.54, for a total transaction of $308,647.02. Following the completion of the sale, the chief financial officer now owns 12,500 shares of the company's stock, valued at $156,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Garry Ph.D. Nolan sold 3,810 shares of the company's stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $13.31, for a total transaction of $50,711.10. Following the sale, the director now directly owns 618,978 shares of the company's stock, valued at approximately $8,238,597.18. The disclosure for this sale can be found here. Insiders sold 30,523 shares of company stock valued at $387,201 over the last 90 days. Corporate insiders own 9.20% of the company's stock.

Institutional Trading of Akoya Biosciences

Several large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC purchased a new stake in Akoya Biosciences during the 4th quarter valued at about $1,254,000. Legato Capital Management LLC purchased a new stake in Akoya Biosciences during the 4th quarter valued at about $467,000. DekaBank Deutsche Girozentrale purchased a new stake in Akoya Biosciences during the 4th quarter valued at about $522,000. ZWJ Investment Counsel Inc. grew its stake in Akoya Biosciences by 3.7% during the 4th quarter. ZWJ Investment Counsel Inc. now owns 42,000 shares of the company's stock valued at $402,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Akoya Biosciences by 16.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 75,837 shares of the company's stock valued at $891,000 after purchasing an additional 10,547 shares during the last quarter. Hedge funds and other institutional investors own 34.61% of the company's stock.

Akoya Biosciences Company Profile

(Get Rating)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

Recommended Stories

• Get a free copy of the StockNews.com research report on Akoya Biosciences (AKYA)
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.